. Author manuscript; available in PMC: 2009 Oct 1.

Published in final edited form as: Calcif Tissue Int. 2008 Sep 24;83(4):251–259. doi: 10.1007/s00223-008-9170-1

Table 3.

Acid-Suppressive Medication Use and Rates of Bone Loss at the Total Hip

	SOF Women (n=2856)		MrOS Men (n=4236)
	Age Adjusted^a	Multivariate Adjusted^b	Age Adjusted^a	Multivariate Adjusted^b

PPI user	-0.62 (p=0.29)	-0.70 (p=0.08)	-0.40 (p=0.28)	-0.38 (p=0.39)
H2RA user	-0.55 (p=0.50)	-0.57 (p=0.30)	-0.49 (p=0.01)	-0.44 (p=0.09)
PPI or H2RA user	-0.57 (p=0.28)	-0.61 (p=0.08)	-0.44 (p=0.02)	-0.41 (p=0.09)
Non-user	-0.49 (referent)	-0.48 (referent)	-0.35 (referent)	-0.34 (referent)

Adjusted for age and clinic.

Adjusted for age, clinic, race, BMI, alcohol use, exercise, oral or inhaled corticosteroid use, NSAID use, calcium supplement use, osteoporosis medication use, and self reported health, concurrent weight change and initial total hip BMD. SOF results are adjusted for caffeine intake and estrogen use. MrOS results are adjusted for smoking and history of stomach surgery.